Program
Anti-CD38 Antibody-drug Conjugate ABBV-438
In AbbVie’s pipeline, CD38
. Its studies are mostly in Multiple Myeloma, led by AbbVie.
Furthest: phase 1, since Feb 9, 20261 company-led study, 1 open or runningNext primary completion: Nov 2031 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 11 open or running | phase 1since Feb 9, 2026 | Feb 9, 2026 | Nov 2031phase 1 · NCT07409246 |
- Named in AbbVie’s own pipeline as
ABBV-438
, phase 1, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 9, 2026First study: phase 1 study in Multiple MyelomaFirst studyNCT07409246 · 127 planned · United States, China, Israel and more
Ahead
- Nov 2031Primary completion: phase 1 study in Multiple MyelomaNCT07409246
TargetBeta
“CD38”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed a monoclonal antibody directed against the human cell surface glycoprotein and tumor-associated antigen (TAA) CD38 ”NCIt, by rule
Other programs on CD38
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| daratumumabrule | Johnson & Johnson | phase 4 | 44 |
| isatuximabrule | Sanofi | phase 3 | 23 |
| felzartamabrule | Biogen | phase 3 | 15 |
| mezagitamabrule | Takeda | phase 3 | 11 |
| lumrotatugrule | Keymed Biosciences | phase 3 | 10 |
| Anti-CD38 Monoclonal Antibody SCTC21Crule | Sinocelltech Group | phase 3 | 5 |
| sanritatugrule | Hangzhou Sumgen Biotech | phase 3 | 5 |
| CID-103rule | CASI Pharmaceuticals | phase 2 | 4 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| Anti-CD38 Monoclonal Antibodyrule | Chongqing Genrix Biopharmaceutical | phase 2 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07409246Multiple Myeloma · United States, China, Israel and more | 1 | Recruiting | Nov 2031 | 127 |
How it is read
Names in the registry
- “ABBV-438”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.